| __timestamp | Taro Pharmaceutical Industries Ltd. | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 91733000 | 7461000 |
| Thursday, January 1, 2015 | 87644000 | 11960000 |
| Friday, January 1, 2016 | 92365000 | 13108000 |
| Sunday, January 1, 2017 | 85656000 | 17501000 |
| Monday, January 1, 2018 | 88196000 | 22472000 |
| Tuesday, January 1, 2019 | 89971000 | 24286000 |
| Wednesday, January 1, 2020 | 93413000 | 29689000 |
| Friday, January 1, 2021 | 91355000 | 38837000 |
| Saturday, January 1, 2022 | 113676000 | 47489000 |
| Sunday, January 1, 2023 | 198366000 | 53379000 |
| Monday, January 1, 2024 | 218935000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Taro Pharmaceutical Industries Ltd. and Xencor, Inc. over the past decade.
Taro has consistently outpaced Xencor in SG&A spending, with a notable increase of over 130% from 2014 to 2023. In 2023, Taro's expenses surged to nearly double their 2022 figures, highlighting a strategic shift or expansion. In contrast, Xencor's expenses grew steadily, peaking in 2023 with a 617% increase since 2014.
This trend underscores Taro's aggressive market strategies compared to Xencor's more conservative approach. However, the absence of data for 2024 suggests potential changes in reporting or strategic pivots. Understanding these dynamics is essential for investors and stakeholders aiming to navigate the pharmaceutical sector's complexities.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Comparing SG&A Expenses: Catalyst Pharmaceuticals, Inc. vs Xencor, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Ligand Pharmaceuticals Incorporated or Xencor, Inc.
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends